Novo Holdings, Jeito Capital and Asabys Partners led a €78m Series A round in Augustine Therapeutics.

Novo Holdings, a holding and investment company, Jeito Capital, a global investment company, and Asabys Partners, a firm in the life science venture capital industry, led a €78m Series A round in Augustine Therapeutics, a biotechnology company focused on developing new therapies for neuromuscular, neurodegenerative and cardio-metabolic diseases, with participation from Eli Lilly and Company, AdBio Partners, V-Bio Ventures, PMV, VIB, Gemma Frisius Fund, Charcot-Marie-Tooth (CMT) Research Foundation and Newton Biocapital. "This investment illustrates the potential of Augustine to bring exciting innovation in therapeutic areas where patients have limited or no treatment options. We are delighted to co-lead this financing to realize Augustine’s potential, which stands out for both the quality of its research and the expertise of Gerhard and his team. We look forward to our future collaboration, which shares a common ambition: to accelerate clinical development in order to bring these innovations to patients," Mehdi Ainouche, Jeito Capital Senior Principal.